Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 86 clinical trials
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will …

residual tumor
cellular therapy
stem cell transplantation
gilbert's syndrome
inotuzumab
  • 14 views
  • 13 Feb, 2022
  • 24 locations
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 18 subjects to receive GC022F therapy.

pericardial effusion
pleural effusion
tyrosine kinase inhibitor
tyrosine
alt/ast
  • 0 views
  • 25 Jan, 2021
  • 1 location
Study of IFN- Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia R/R-ALL

The purpose of this study is to evaluate the safety and efficacy of IFN- combined with CAR-T cell therapy in relapsed and refractory acute lymphoblastic leukemia (R/R ALL).

  • 0 views
  • 25 Jan, 2021
  • 1 location
Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL (ALL-001)

-cell acute lymphoblastic leukemia (B-ALL). Two re-induction regimens will be tested (one without pegaspargase and one including pegaspargase) and participants will be followed for disease status

vincristine
methotrexate
prednisone
cytarabine
lymphoma
  • 0 views
  • 18 Jun, 2022
  • 4 locations
Phase 1 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a Phase 1, first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic

cellular therapy
chemotherapy regimen
  • 14 views
  • 06 Jun, 2022
  • 7 locations
CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia

This study aims to evaluate the safety and feasibility of CTA101 in treating patients with relapsed or refractory CD19+ B-cell acute lymphoblastic leukemia.

ejection fraction
oximetry
monoclonal antibodies
b-cell acute lymphoblastic leukemia
lymphoid leukemia
  • 15 views
  • 17 Feb, 2022
  • 1 location
Study of alloCART-19 Cell Therapy in Pediatric Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

The purpose of this study is to evaluate the safety and tolerability of CD19-Directed Allogeneic Chimeric Antigen Receptor T- cell (alloCART-19)therapy in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaALL.

leukemia
stem cell transplantation
lymphoblast count
cancer chemotherapy
cyclophosphamide
  • 0 views
  • 27 Feb, 2022
  • 1 location
  • 0 views
  • 22 Jan, 2021
  • 1 location
Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

This is an open, single-arm, prospective clinical study to evaluate the safety and efficacy of anti CD19 and CD22 CAR-T cell in the treatment of R/R B-ALL.

  • 0 views
  • 21 Mar, 2022
  • 1 location
  • 0 views
  • 19 Jun, 2022
  • 2 locations